Biologic therapies targeting type 2 inflammation significantly cut COPD exacerbations and improved lung function

Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder characterized by chronic airway inflammation and persistent airflow limitation. A significant subset of patients exhibits type 2 (T2) inflammation, driven by cytokines like IL-5, IL-4, and IL-13. Current standard-of-care often falls short for these patients, leading to frequent exacerbations and progressive lung function decline. Biologic therapies targeting these specific T2 inflammatory pathways have emerged as a potential precision medicine approach, but their overall clinical efficacy and safety across different targets required a comprehensive assessment.

Researchers conducted a systematic review and meta-analysis of seven randomized controlled trials (RCTs) evaluating biologic therapies in patients with COPD and biomarker-defined T2 inflammation. The interventions included biologic therapies targeting interleukin (IL)-5, IL-5 receptor α, IL-4/IL-13, or thymic stromal lymphopoietin (TSLP). Primary outcomes assessed were the rate of moderate or severe COPD exacerbations, lung function measured by forced expiratory volume in 1 s (FEV₁) changes, health-related quality of life using the St George's Respiratory Questionnaire (SGRQ), and serious adverse events. Random-effects meta-analyses were performed for comparable studies.

Biologic therapies targeting T2 inflammation significantly reduced the rate of moderate or severe COPD exacerbations compared with placebo, showing a rate ratio of 0.77 (95% CI 0.72 to 0.83; p<0.001; I²=0%). Lung function also improved modestly, with a pooled increase in FEV₁ of 43 mL (95% CI 12.5 to 73.6; p=0.006; I²=55.3%). Health-related quality of life, as measured by SGRQ total scores, improved by -2.46 units (95% CI -3.43 to -1.49; p<0.001; I²=0%).